Antipsychotic-like vs cataleptogenic actions in mice of novel antipsychotics having D2 antagonist and 5-HT1A agonist properties

Neuropsychopharmacology

Volumn 31, Issue 9, 2006, Pages 1869-1879

  Bardin, Laurent ^a   Kleven, Mark S ^b   Barret Grévoz, Catherine ^a   Depoortère, Ronan ^a   Newman Tancredi, Adrian ^a  

^a INSTITUT DE RECHERCHE PIERRE FABRE   (France)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

5 HT1A receptor; Antipsychotic; Apomorphine; Catalepsy; Dopamine D2 receptor; Mice

Indexed keywords

3 [[(2 CHROMANYLMETHYL)AMINO]METHYL] 5 (4 FLUOROPHENYL)PYRIDINE; 5 [4 [5 (4 FLUOROPHENYL) 3 PYRIDINYLMETHYL] 1 PIPERAZINYL] 1,4 BENZODIOXAN; 8 BENZYL N [(7 CHLORO 2,3 DIHYDRO 1,4 BENZODIOXIN 1 YL)METHYL] 8 AZABICYCLO[3.2.1]OCTANE 3 METHANAMINE; ARIPIPRAZOLE; BIFEPRUNOX; CLOZAPINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; EMONAPRIDE; END 128130; ETICLOPRIDE; FLUPHENAZINE; HALOPERIDOL; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDINYL)CYCLOHEXANECARBOXAMIDE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; N [4 [(3 CHLORO 4 FLUOROPHENYL)AMINO] 7 [3 (MORPHOLIN 4 YL)PROPOXYL]QUINAZOLIN 6 YL]PROP 2 ENAMIDE MESYLATE; NEUROLEPTIC AGENT; OLANZAPINE; RACLOPRIDE; RISPERIDONE; SARIZOTAN; SEROTONIN 1A AGONIST; SSR 181507; UNCLASSIFIED DRUG; ZIPRASIDONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CATALEPSY; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; MALE; NONHUMAN; PRIORITY JOURNAL; PSYCHOSIS; RECEPTOR AFFINITY; RECEPTOR BLOCKING;

ANIMALS; ANTIPSYCHOTIC AGENTS; APOMORPHINE; CATALEPSY; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; MICE; PIPERAZINES; PYRIDINES; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTORS, DOPAMINE D2; SEROTONIN AGONISTS; SEROTONIN ANTAGONISTS; STEREOTYPED BEHAVIOR;

EID: 33747342674     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1300940     Document Type: Article

References (57)

1. 1A receptor agonist properties of the antipsychotic nemonapride: comparison with bromerguride and clozapine. Eur J Pharmacol 334: 141-147.
2. 1A receptor in schizophrenia: a promising target for novel atypical neuroleptics ? J Psychopharmacol. 15: 37-46.
3. 1A receptor by clozapine measured using PET scanning. J Psychopharmacol 14: PG20.
4. 1A receptor agonist and dopamine receptor ligand. 1. Neurochemical profile. J Neural Transm 111: 113-126.
5. 1A agonists in the treatment of depression? Biol Psychiatry 53: 193-203.
6. Brunello N, Masotto C, Steardo L, Markstein R, Racagni G (1995). New insights into the biology of schizophrenia through the mechanism of action of clozapine. Neuropsychopharmacology 13: 177-213.
7. Buchanan RW, Kreyenbuhl J, Zito JM, Lehman A (2002). Relationship of the use of adjunctive pharmacological agents to symptoms and level of function in schizophrenia. Am J Psychiatry 159: 1035-1043.
8. 1A receptors by clozapine in the primate brain: a PET study. Psychopharmacology 166: 234-240.
9. Christoffersen CL, Meltzer LT (1998). Reversal of haloperidol-induced extrapyramidal side effects in cebus monkeys by 8-hydroxy-2-(di-n-propylamino) tetralin and its enantiomers. Neuropsychopharmacology 18: 399-402.
10. 1A receptor agonist. I: Neurochemical and electrophysiological profile. Neuropsychopharmacology 28: 2064-2076.
11. 1A receptors. Psychopharmacology 162: 168-177.
12. Daniel DG, Zimbroff DL, Potkin SG, Reeves KR, Harrigan EP, Lakshminarayanan M (1999). Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group. Neuropsychopharmacology 20: 491-505.
13. 1A receptor agonist. II: Behavioral profile predictive of an atypical antipsychotic activity. Neuropsychopharmacology 28: 1889-1902.
14. 1A receptor antagonist, WAY-100635. Eur J Pharmacol 281: 81-88.
15. Fray PJ, Sahakian BJ, Robbins TW, Koob GF, Iversen SD (1980). An observational method for quantifying the behavioural effects of dopamine agonists: contrasting effects of d-amphetamine and apomorphine. Psychopharmacology 69: 253-259.
16. 1A receptor agonist: In vitro and in vivo neuropharmacology. Eur Neuropsychopharmacol 12: S277.
17. Hirose T, Uwahodo Y, Yamada S, Miwa T, Kikuchi T, Kitagawa H et al (2004). Mechanism of action of aripiprazole predicts clinical efficacy and a favourable side-effect profile. J Psychopharmacol 18: 375-383.
18. Honey GD, Bullmore ET, Soni W, Varatheesan M, Williams SCR, Sharma T (1999). Differences in frontal cortical activation by a working memory task after substitution of risperidone for typical antipsychotic drugs in patients with schizophrenia. Proc Nat Acad Sci USA 96: 13432-13437.
19. Hubert JJ (1984). Bioassay. Kendall/Hunt: Dubuque, IA.
20. 1A receptor agonism on antipsychotic drug-induced dopamine release in rat striatum and nucleus accumbens. Brain Res 858: 252-263.
21. 2 receptor antagonists to inhibit methylphenidate-induced behaviors in rats. Eur J Pharmacol 313: 25-34.
22. 1A receptor activation in attenuation of catalepsy induction in rats. Neuropharmacology 49: 135-143.
23. 1A properties: evidence for lowered EPS liability. Coll Inter Neuro Psychopharmacol Abs 02: 503.
24. 1A receptor activation and antidepressant-like effects: F13714 has high efficacy and marked antidepressant potential. Eur J Pharmacol 420: 103-112.
25. Kudo Y, Ikawa G, Kawakita Y, Saito M, Sakai T, Nakajima T et al (1989). A double-blind comparative study of a new benzamide compound YM-09151 with sulpiride in schizophrenia. J Clin Ther Med 5: 2149-2175.
26. Kuzhikandathil EV, Sayed N, Pasuit JB, Bartoszyk GD (2004). Differential effects of sarizotan on dopamine receptor function. Soc Neurosci Abs 163: 6.
27. Lawler CP, Prioleau C, Lewis MM, Mak C, Jiang D, Schetz JA et al (1999). Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology 20: 612-627.
28. Litchfield JT, Wilcoxon F (1949). A simplified method of evaluating dose-effect experiments. J Pharmacol Exp Ther 96: 99-113.
29. McCreary AC, Glennon J, Tuinstra T, Herremans AHJ, Van der Heyden JAM, Feenstra R et al (2002). SLV313: A novel antipsychotic with additional antidepressant and anxiolytic-like actions. Eur Neuropsychopharmacology 12: S274.
30. Meltzer HY (1995). Atypical antipsychotic drugs. In: Bloom FE, Kupfer DJ (eds). Psychopharmacology: The Fourth Generation of Progress. Raven Press Ltd: New York. pp 1277-1288.
31. Meltzer HY, Li Z, Kaneda Y, Ichikawa J (2003). Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuro-psychopharmacol Biol Psychiatr 27: 1159-1172.
32. 1A receptors. J Pharmacol Exp Ther 295: 853-861.
33. 1A agonist properties: II. Functional profile in comparison to clozapine and haloperidol. J Pharmacol Exp Ther 286: 1356-1373.
34. Moore NC, Meyendorff E, Yeragani V, LeWitt PA, Gershon S (1987). Tiaspirone in schizophrenia. J Clinical Psychopharmacology 7: 98-101.
35. 1A receptors: affinity, efficacy and potential implications for treatment of schizophrenia. Int J Neuropsychopharmacol 8: 1-16.
36. 35S]GTPgγS binding study. Eur J Pharmacol 355: 245-256.
37. Pantelis C, Barnes TRE (1993). Acute exacerbation of psychosis with buspirone ? J Psychopharmacol 7: 295-300.
38. 1A receptor activation and anti-cataleptic effects: high-efficacy agonists maximally inhibit haloperidol-induced catalepsy. Eur J Pharmacol 453: 217-221.
39. Prinssen EPM, Kleven MS, Koek W (1996). Effects of dopamine antagonists in a two-way active avoidance procedure in rats: interactions with 8-OH-DPAT, ritanserin, and prazosin. Psychopharmacology 128: 191-197.
40. 1A receptor agonist properties. Eur J Pharmacol 356: 189-192.
41. 1A ligands in preclinical behavioral models for antipsychotic and extrapyramidal effects. Psychopharmacology 144: 20-29.
42. 1A receptors. Eur J Pharmacol 395: 143-147.
43. Protais P, Costentin J, Schwartz JC (1976). Climbing behaviour induced by apomorphine in mice: a simple test for the study of dopamine receptors in striatum. Psychopharmacology 50: 1-6.
44. 1A receptor activation. Eur J Pharmacol 338: 3-5.
45. Roth BL, Sheffler DJ, Kroeze WK (2004). Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discovery 3: 353-359.
46. 1A receptor antagonists. Behav Brain Res 73: 153-156.
47. Seeger TF, Seymour PA, Schmidt AW, Zorn SH, Schulz DW, Lebel LA et al (1995). Ziprasidone (CP-88,059): A new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther 275: 101-113.
48. Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu LX, Sibley DR et al (2003). Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 28: 1400-1411.
49. Sumiyoshi T, Matsui M, Nohara S, Yamashita I, Kurachi M, Sumiyoshi C et al (2001a). Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment. Am Journal of Psychiatry 158: 1722-1725.
50. 1A agonist, on memory function in schizophrenia. Biol Psychiatry 49: 861-868.
51. Tallarida RJ, Murray RG (1987). Manual of Pharmacological Calculations with Computer Programs. Springer Verlag: New York.
52. 2 receptor antagonism with serotonin reuptake inhibition. Soc Neurosci Abs 894: 19.
53. Urban JD, Gay EA, Mailman RB (2004). Functional selectivity as a mechanism of action of newer atypical antipsychotic drugs. Soc Neurosci Abs 163: 4.
54. Waddington JL (1986). Psychopharmacological studies in rodents: stereotaxic intracerebral injections and behavioral assessment. In: Joseph MH, Waddington JL (eds). Working Methods in Neuropsychopharmacology. Manchester University Press: Manchester. pp 1.
55. Wadenberg ML (1996). Serotonergic mechanisms in neuroleptic-induced catalepsy in the rat. Neurosci Biobehav Rev 20: 325-339.
56. Wolf W (2003). DU127090. Current Opin Invest Drugs 4: 72-76.
57. Yoshida K, Sugita T, Higuchi H, Hishikawa Y (1998). Effect of tandospirone on tardive dyskinesia and parkinsonian symptoms. Eur Psychiatry 13: 421-422.